FutureMeds: Corporate Profile and Operational Overview
Introduction and Mission
FutureMeds (FutureMeds Ltd) is a leading independent European Site Network and Decentralised Clinical Trial (DCT) service provider headquartered in the United Kingdom. Founded in 2019, the company specializes in accelerating the drug development process by conducting patient-centric clinical trials for global pharmaceutical sponsors and Contract Research Organizations (CROs).
The organization's mission is to transform the clinical trial landscape by improving patient access to life-changing treatments through a combination of dedicated physical research sites and innovative remote monitoring technologies. FutureMeds serves as a critical bridge between the medical research community and the patients who stand to benefit from next-generation therapies.
Continue…
Core Operations: The Dedicated Site Network
The backbone of FutureMeds is its integrated network of "Dedicated Research Sites." Unlike traditional hospital-based research, which often competes for resources with routine clinical care, FutureMeds sites are exclusively focused on clinical research. This dedicated model allows for faster study startup, higher quality data collection, and a more streamlined experience for participants.
Regional Footprint
- United Kingdom: FutureMeds maintains a significant presence across Britain with key sites in London, Newcastle, Glasgow, Teesside, Liverpool (Wirral), and Birmingham.
- European Expansion: Beyond the UK, the group operates across a total of 7 European countries, including Poland, Bulgaria, Romania, and Germany (via its subsidiary Emovis), managing a total of over 28 research sites.
Products and Services for Sponsors and CROs
FutureMeds provides end-to-end site management services designed to de-risk clinical programs and ensure regulatory compliance.
1. Patient Recruitment and Retention
Utilizing its proprietary "People Access Collaboration Truth" (P.A.C.T.) framework, FutureMeds leverages extensive databases and community outreach to identify eligible participants.
* Rapid Enrolment: The company specializes in high-volume recruitment across diverse therapeutic areas.
* Diversity Initiatives: FutureMeds UK works closely with the NHS and local communities to ensure clinical trials are accessible to people from all backgrounds, improving the real-world applicability of study data.
2. Decentralised Clinical Trials (DCT) Solutions
Recognizing the shift toward remote healthcare, FutureMeds has developed a robust DCT platform that reduces the "patient burden" by bringing the trial to the participant.
* HomeCare Network: A network of over 1,400 homecare providers capable of conducting study visits, blood draws, and medication administration at a patient's residence.
* Telemedicine & Remote Monitoring: Utilizing wearable devices and mobile applications to track health metrics in real-time, reducing the frequency of required clinic visits.
3. Therapeutic Expertise
The organization supports Phase II through Phase IV clinical trials across more than 30 therapeutic areas, including:
* Cardiovascular Disease
* Respiratory Conditions (Asthma, COPD)
* Neurology (Migraines, Alzheimer?s)
* Metabolic Disorders (Diabetes, Obesity)
* Dermatology and Immunology
Participant Services and Experience
For volunteers and patients, FutureMeds offers an alternative pathway to healthcare that provides access to treatments not yet available on the general market.
- Dedicated Medical Teams: Every participant is supported by a team of experienced Principal Investigators (PIs), certified research nurses, and study coordinators.
- No-Cost Participation: Patients receive all study-related medications, medical examinations, and laboratory tests at no cost.
- Reimbursement: In many cases, participants are eligible for reimbursement for their time and travel expenses related to the study.
- Ethical Oversight: All trials managed by FutureMeds are conducted under strict adherence to Good Clinical Practice (GCP) and are reviewed by independent ethics committees.
Corporate Growth and Strategic Partnerships
FutureMeds has seen rapid expansion through both organic growth and strategic acquisitions. A notable milestone was the acquisition of CPS Research in Glasgow, which bolstered its capabilities in complex outpatient studies. The company is backed by private equity (including Phoenix Equity Partners), providing the financial infrastructure to continue its expansion into new therapeutic domains and geographic markets.
FutureMeds remains a pivotal player in the "GlobalReady" clinical research ecosystem, employing nearly 400 professionals dedicated to finding answers faster and bringing the future of medicine to patients today.
